Overview

• Dr. Cyriac Abby Philips said a patient lost 40 kilograms in six months after starting tirzepatide, describing marked gains in confidence and well-being.
• He advised use for adults with type 2 diabetes seeking better glucose control with weight loss, for those with obesity or overweight with comorbidities, and for patients with obstructive sleep apnea and obesity.
• He cautioned against use for anyone with a personal or family history of medullary thyroid cancer or MEN2, for people with severe gastrointestinal disease such as gastroparesis, and for those allergic to tirzepatide.
• He described common side effects as typically mild and transient—nausea, diarrhoea, decreased appetite, vomiting, constipation, bloating, abdominal pain—while listing rare risks including pancreatitis, acute gallbladder disease, acute kidney injury from dehydration, severe gastric reactions, and retinopathy complications.
• He cited broader benefits reported in studies—lower HbA1c, 15–21% weight loss in some groups, improved cardiometabolic, kidney and liver metrics—and articles noted FDA approvals for diabetes and chronic weight management and Lilly’s India launch in March 2025.